Organization (Other)
Scott and White Hospital & Clinic
ClinicalTrials.gov lists Scott and White Hospital & Clinic as lead sponsor of 14 trials. It has 10 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Scott and White Hospital & Clinic: 14 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (40)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 5 |
| Diabetes Mellitus | 4 |
| Headache | 4 |
| Hemorrhage | 4 |
| Metrorrhagia | 3 |
Showing 5 of 40 disease areas.
Trials by start year as sponsor or collaborator (13)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2018 | 1 |
| 2013 | 1 |
| 2012 | 1 |
| 2011 | 2 |
| 2010 | 2 |
| 2009 | 4 |
| 2008 | 5 |
| 2007 | 1 |
| 2006 | 2 |
Showing 10 of 13 years.
Recruitment duration, a model prediction: none of the 14 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (10)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Norethindrone acetate pretreatment | 1 |
| 0.25% Bupivacaine with Epinephrine (1:200,000) | 1 |
| 1% Lidocaine with Epinephrine (1:100,000) | 1 |
| 0.5% Lidocaine, 0.125 Bupivacaine, and epi (1:150,000) | 1 |
| Aprepitant, Dexamethasone, Ondansetron | 1 |
Showing 5 of 10 approved assets.
Journals published in (26)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2 |
| Patient education and counseling | 2 |
| Pediatrics | 2 |
| Vaccine | 2 |
| American journal of epidemiology | 1 |
Showing 5 of 26 journals.
Organization relationships (6)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Virogen Biotechnology Inc. | Co sponsors trial with | 2 |
| University of Arkansas | Co sponsors trial with | 1 |
| Endo USA Inc., a Keenova Therapeutics Company | Co sponsors trial with | 1 |
| James Graham Brown Cancer Center | Co sponsors trial with | 1 |
| Anodyne Therapy, LLC | Co sponsors trial with | 1 |
Showing 5 of 6 relationships.
Latest dated events (23)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2018-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2013-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2012-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2011-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 23 events.
Biomarker capability evidence (12)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| CPE | Trial collaborator | Named in trial inclusion criteria |
| PLAT | Trial collaborator | Named in trial exclusion criteria |
| ALB | Trial collaborator | Mentioned in trial text |
Showing 5 of 12 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.